Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

Launched by CHINESE PLA GENERAL HOSPITAL · Jan 10, 2024

Keywords

ClinConnect Summary

This clinical trial is examining how combined treatments of immunotherapy and chemotherapy affect the tumor microenvironment (the area around the tumor) in patients with advanced gastric cancer. Researchers want to learn how these treatments work together and how they might impact different patients based on their responses to the therapy. By studying tissue samples from patients before and after treatment, the goal is to better understand what makes the treatment effective for some patients and less so for others.

To participate in this trial, patients should be between 18 and 70 years old and have advanced gastric cancer that has been confirmed by a doctor. They should be in good overall health and not have received certain other cancer treatments in the past five years. Participants will receive a specific chemotherapy regimen along with either nivolumab or sintilimab, which are types of immunotherapy. This study is currently looking for volunteers, and those who join can expect to have their health closely monitored during the treatment process. It's a chance to contribute to important research that may improve how gastric cancer is treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Non-bedridden, aged 18 to 70 years old;
• • Eastern Cooperative Oncology Group (ECOG) score is 0 to 1;
• • Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1;
• • Advanced gastric cancer;
• • Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab
• Exclusion Criteria:
• • History of other malignant diseases in the last 5 years;
• • Prior chemotherapy, radiotherapy or immunotherapy;
• • Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.